Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 43547-276

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 43547-276). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Solco Healthcare Us, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (41d7651e B91a 4118 8719 Bf2f663d82a2 01)

FDA Label Image

Figure 1 (41d7651e B91a 4118 8719 Bf2f663d82a2 02)

Figure 1 (41d7651e B91a 4118 8719 Bf2f663d82a2 02)
This appears to be a table with some numerical values and medication names mentioned such as Donepezil hydrochloride and Placebo. The column headings mention ADAS-cog Change from Baseline, Clinical Improvement, and Weeks of Drug Treatment. It is not possible to provide further information or description based on this text alone.*
FDA Label Image

Figure 2 (41d7651e B91a 4118 8719 Bf2f663d82a2 03)

Figure 2 (41d7651e B91a 4118 8719 Bf2f663d82a2 03)
This text seems to be showing some kind of report on the results of a study. It includes information about a "cumulative percentage of patents" and a "change in ADAS-cog" score. It also lists different groups, including a placebo group, and shows the percentage change in the ADAS-cog score for each group. The report seems to be comparing two different doses of a drug. However, without more context it is difficult to determine what kind of study or drug is being discussed.*
FDA Label Image

Figure 3 (41d7651e B91a 4118 8719 Bf2f663d82a2 04)

Figure 3 (41d7651e B91a 4118 8719 Bf2f663d82a2 04)
This appears to be a table or chart showing the percentage of patients who took either Donepezil hydrochloride (at 10mg/day or 3mg/day) or a placebo, and their corresponding improvement or worsening as rated by the CIBIC-plus scale. The ratings range from "Markedly Improved" to "Markedly Worse".*
FDA Label Image

Figure 4 (41d7651e B91a 4118 8719 Bf2f663d82a2 05)

Figure 4 (41d7651e B91a 4118 8719 Bf2f663d82a2 05)
This text provides a table showing the mean ADAS-cog change from baseline for different drug treatments and placebo, over weeks of treatment. The drugs mentioned are Donepesil hydrochloride 10mg/day and Donepexi hydrochloride 5mg/day. The symbol "+" with a value of 5E is also present. This text likely pertains to a study evaluating the effectiveness of various drugs in treating cognitive decline in a clinical setting.*
FDA Label Image

Figure 5 (41d7651e B91a 4118 8719 Bf2f663d82a2 06)

FDA Label Image

Figure 6 (41d7651e B91a 4118 8719 Bf2f663d82a2 07)

Figure 6 (41d7651e B91a 4118 8719 Bf2f663d82a2 07)
This appears to be a chart or table displaying information about patients receiving Aricept 10mg/day, Aricept 5mg/day, and a placebo. The chart shows different levels of improvement or worsening in patients' CIBIC-plus rating, with various degrees of improvement or decline represented by words ranging from "Markedly Improved" to "Worse." However, without additional context or information, it is not entirely clear what this chart is specifically measuring or used for.*
FDA Label Image

Figure 7 (41d7651e B91a 4118 8719 Bf2f663d82a2 08)

FDA Label Image

Figure 8 (41d7651e B91a 4118 8719 Bf2f663d82a2 09)

Figure 8 (41d7651e B91a 4118 8719 Bf2f663d82a2 09)
The text includes the name of a medication, donepezil hydrochloride, and its dosage, 10 mg per day. There is also a mention of a placebo. The rest of the text appears to be gibberish and not readable.*
FDA Label Image

Figure 9 (41d7651e B91a 4118 8719 Bf2f663d82a2 10)

FDA Label Image

Figure 10 (41d7651e B91a 4118 8719 Bf2f663d82a2 11)

FDA Label Image

Principal Display Panel – 5 mg Bottle Label (41d7651e B91a 4118 8719 Bf2f663d82a2 12)

Principal Display Panel – 5 mg Bottle Label (41d7651e B91a 4118 8719 Bf2f663d82a2 12)
Each tablet contains Beepentydociando g. The dosage is 5o and it comes with an accompanying pack. The storage should be controlled at a temperature of 15°C to 30°C. The tablets should be dispensed in a non-permeable container (USP) by a pharmacist to the patient. Manufactured by Zhefang Huahai Pharmaceutical Co. Ltd in China and distributed by Solco Healthcare US, LLG in Somerset, NJ. Rev. 082020.*
FDA Label Image

Principal Display Panel – 10 mg Bottle Label (41d7651e B91a 4118 8719 Bf2f663d82a2 13)

Principal Display Panel – 10 mg Bottle Label (41d7651e B91a 4118 8719 Bf2f663d82a2 13)
Each film-coated tablet contains 0mg of Boegent tydtociands. The dosage that accompanies the package is not available. Store at controlled room temperature, between 15°C to 30°C (59°F to 86°F). Manufactured by Znefang Huahai Pharmaceutical Co, Ltd, distributed by Solco Healthcare US, LG. Pharmacist should dispense in a tight container (USP) and Tablets, USP to the patient as per the information given on the package.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.